Cell or Molecular Dysfunction

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

1 week ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

2 weeks ago talkbio0Tagged Antibodies, BioArctic, Blood - brain barrier anatomy, BrainTransporter platform, Leqembi, milestone payments, Nerve Degeneration, Novartis, Partnership, royalties

Novartis; BioArctic; BrainTransporter platform; blood-brain barrier; neurodegeneration; Leqembi; partnership; antibody; milestone payments; royalties

Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance

1 month ago talkbio0Tagged CEO, Changing, drug competition, growth outlook, guidance cut, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Sales - occupational activity, Transition Mutation

Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

3 months ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

4 months ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry